FDA Advisory Committee Votes in Favor of Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 19, 2024
Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia March 19, 2024
Global Ph 3 Clinical Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by EMA March 19, 2024
FDA clears INDs for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b March 19, 2024
Rolling NDA submitted to the FDA for UGN-102; 12-month duration of response data from ENVISION expected to support completion of NDA submission March 19, 2024
MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment March 19, 2024
FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma March 19, 2024
FDA accepts the NDA for ensartinib for the treatment of adult patients with metastatic ALK-positive NSCLC March 19, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
